Short-Term Rivastigmine Treatment Reduces EEG Slow-Wave Power in Alzheimer PatientsAdler G. · Brassen S.
Day Clinic for the Elderly and Clinical Neurophysiology Service, Central Institute of Mental Health, Mannheim, Germany
The effects of a 5-day treatment with rivastigmine on the resting EEG power spectrum were studied in 15 mildly to moderately ill Alzheimer patients. In these patients, beta power was positively correlated with cognitive performance and negatively correlated with functional impairment. Rivastigmine produced a decrease in delta and theta power with no effect of hemisphere and electrode position. Delta power decrease reflects the cerebral cholinergic action of rivastigmine and may thus allow a quantitative assessment of its CNS effects.
Priv.-Doz. Dr. Georg Adler
Zentralinstitut für Seelische Gesundheit, Postfach 12 21 20
D–68072 Mannheim (Germany)
Tel. +49 621 1703 792, Fax +49 621 2 34 29
Number of Print Pages : 4
Number of Figures : 2, Number of Tables : 0, Number of References : 33
Neuropsychobiology (International Journal of Experimental and Clinical Research in Biological Psychiatry, Pharmacopsychiatry, Biological Psychology/Pharmacopsychology and Pharmacoelectroencephalography)
Founded 1975 by J. Mendlewicz (Brussels)
Official Journal of the International Pharmaco-EEG Society (IPEG)
Vol. 43, No. 4, Year 2001 (Cover Date: Released May 2001)
Journal Editor: J. Mendlewicz, Brussels; B. Saletu, Vienna; P. Netter, Giessen; W.M. Herrmann, Berlin
ISSN: 0302–282X (print), 1423–0224 (Online)
For additional information: http://www.karger.com/journals/nps